226950 - Olix Pharmaceuticals, Inc.

226950 Summary

Biopharma

Stock Price & Overview

₩95,900 +4,100 (+4.47%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩95,900 ≈ US$69 · Market cap ₩2.0tn (≈ $1.4bn)

226950 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total Revenue	14.7	5.7	17.1	9.3	3.7	2.5	1.1	0.3	0.2	0.4
Cost of Revenue	—	—	—	0.0	0.3	0.7	—	—	—	—
Selling, General & Administrative	44.6	36.6	35.2	31.7	27.6	18.0	—	—	—	—
Operating Income	-30.0	-30.9	-18.2	-22.4	-24.2	-16.2	-15.1	-8.2	-5.4	-3.8
Finance Income	23.7	3.4	6.6	1.7	0.6	0.5	0.9	0.5	0.1	0.2
Finance Costs	7.3	7.1	5.7	8.5	6.6	4.8	0.0	0.1	0.0	0.0
Pretax Income	-13.3	-41.1	-18.2	-29.1	-30.0	-20.5	-14.2	-7.7	-5.2	-3.7
Income Tax Expense	2.5	-0.4	0.9	-1.0	-0.8	-1.1	0.1	0.0	0.0	0.0
Net Income	-15.7	-40.7	-19.1	-21.9	-30.3	-19.4	-14.4	-7.7	-5.2	-3.7
Total Comprehensive Income	-17.1	-48.9	-22.4	-16.9	-30.3	-19.7	-14.4	-7.9	-5.2	-3.7

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Total Assets	195.4	71.2	102.8	132.7	86.7	78.6	45.2	55.6	21.6	15.1
Current Assets	140.9	15.5	32.1	65.0	52.2	69.0	37.4	48.7	16.2	10.1
Cash & Cash Equivalents	6.4	3.9	12.0	4.9	34.3	11.3	5.0	2.8	0.7	0.6
Inventories	0.4	0.6	0.5	0.7	0.4	0.3	0.4	0.6	0.7	0.0
Trade Receivables	6.2	1.0	5.0	1.1	0.5	0.4	1.4	1.0	0.6	0.6
Non-current Assets	54.5	55.7	70.7	67.6	34.4	9.5	7.8	6.9	5.5	5.1
Property, Plant & Equipment	50.5	51.4	43.9	37.2	31.5	6.2	5.9	5.2	5.1	4.8
Intangible Assets	1.9	1.7	2.0	2.1	2.1	2.5	1.4	1.3	0.3	0.2
Total Liabilities	45.3	52.8	52.5	66.4	67.3	33.2	3.4	0.7	3.0	2.6
Current Liabilities	21.3	30.1	6.6	39.5	40.4	4.5	2.8	0.3	1.0	0.8
Non-current Liabilities	24.0	22.7	45.9	26.9	26.9	28.7	0.6	0.4	1.9	1.8
Total Equity	150.1	18.5	50.3	66.2	19.4	45.4	41.8	54.9	18.7	12.6
Share Capital	11.1	9.2	8.4	8.4	6.9	6.8	3.3	3.3	2.6	2.3
Retained Earnings	-191.6	-167.8	-122.9	-103.2	-84.3	-54.4	-34.8	-20.2	-12.3	-7.2

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Cash from Operating Activities	-15.9	-28.0	-21.2	-30.7	-19.1	-3.8	-10.7	-8.4	-4.8	-3.4
Cash from Investing Activities	-104.9	1.0	34.4	-54.8	15.5	-31.4	12.6	-31.7	-5.8	-7.8
Cash from Financing Activities	123.8	18.5	-6.1	56.0	26.6	41.7	0.2	42.3	10.7	9.9
Net Change in Cash	2.5	-8.1	7.1	-29.4	23.0	6.4	2.1	2.1	0.0	-1.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	2.6	3.6	4.5	2.9	6.3	1.0	0.0	0.3	4.6	0.8
Selling, General & Administrative	16.6	14.4	13.0	11.2	11.2	9.2	7.7	9.7	8.4	10.9
Operating Income	-14.0	-10.8	-8.5	-8.3	-5.0	-8.2	-7.6	-9.4	-3.8	-10.1
Finance Income	3.3	0.9	22.5	0.4	0.6	0.2	2.4	0.3	0.4	0.3
Finance Costs	0.3	0.8	-1.4	0.4	2.5	5.9	-1.1	1.3	5.9	1.0
Pretax Income	-11.0	-9.8	15.5	-8.7	-6.8	-13.3	-12.1	-10.5	-9.6	-8.9
Income Tax Expense	0.0	0.0	0.1	0.0	2.4	0.0	0.1	0.0	0.0	-0.5
Net Income	-11.0	-9.8	15.4	-8.7	-9.2	-13.3	-12.2	-10.5	-9.6	-8.4
Total Comprehensive Income	-10.8	-9.2	14.8	-8.4	-9.8	-13.7	-11.3	-9.9	-11.0	-16.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	274.1	186.3	195.4	186.6	76.1	69.0	71.2	83.6	92.5	101.9
Current Assets	219.6	132.2	140.9	133.9	23.0	15.3	15.5	15.6	28.3	41.1
Cash & Cash Equivalents	111.5	11.1	6.4	17.3	7.8	8.3	3.9	3.1	6.1	31.7
Inventories	0.4	0.4	0.4	0.5	0.5	0.5	0.6	0.8	0.8	0.8
Trade Receivables	2.5	1.8	6.2	0.6	13.6	0.9	1.0	1.4	2.5	1.5
Non-current Assets	54.5	54.2	54.5	52.7	53.1	53.7	55.7	68.0	64.2	60.8
Property, Plant & Equipment	50.6	50.5	50.5	49.5	50.3	50.8	51.4	51.5	48.1	43.1
Intangible Assets	2.0	1.9	1.9	1.9	1.6	1.6	1.7	1.7	1.8	1.8
Total Liabilities	36.6	41.0	45.3	44.0	52.7	43.0	52.8	66.8	66.1	64.9
Current Liabilities	18.7	20.0	21.3	17.6	24.3	20.9	30.1	37.6	31.3	7.1
Non-current Liabilities	17.9	20.9	24.0	26.4	28.4	22.0	22.7	29.2	34.8	57.8
Total Equity	237.4	145.4	150.1	142.6	23.4	26.0	18.5	16.8	26.4	37.0
Share Capital	11.5	11.1	11.1	11.0	9.9	9.9	9.2	8.6	8.5	8.5
Retained Earnings	-212.4	-201.4	-191.6	-206.0	-197.4	-188.2	-167.8	-151.4	-140.9	-131.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-15.4	-5.7	-12.2	3.2	-6.3	-0.7	-8.2	-7.2	-6.2	-6.4
Cash from Investing Activities	16.1	8.8	1.0	-108.0	1.1	1.0	3.9	4.5	-19.0	11.7
Cash from Financing Activities	99.8	1.3	0.8	114.1	5.0	4.0	4.7	-0.2	-0.3	14.4
Net Change in Cash	100.4	4.7	-10.9	9.5	-0.5	4.4	0.8	-3.0	-25.6	19.7

Consolidated (CFS), from DART. 10 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

226950 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	14.7	+158.3%	+16.3%	+42.8%	—
Operating income	-30.0	—	—	—	—
Net income	-15.7	—	—	—	—
EPS	₩-747	—	—	—	—
Operating cash flow	-15.9	—	—	—	—
Shareholders' equity	150.1	+712.4%	+31.4%	+27.0%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

226950 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Operating margin	-204.4%	-544.6%	-106.6%	-240.1%	-659.4%	-656.4%
Net margin	-107.3%	-716.2%	-111.9%	-234.8%	-824.0%	-783.4%
Return on equity	-18.7%	-118.2%	-32.8%	-51.1%	-93.5%	-44.5%
Return on assets	-11.8%	-46.7%	-16.2%	-20.0%	-36.6%	-31.3%
Operating cash flow / revenue	-108.4%	-494.0%	-124.1%	-329.2%	-518.6%	-151.9%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 226950

Symbol	Last Price
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%
140410Mezzion Pharma Co., Ltd.	₩65,000 +0.0%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.